Dysfibrinogenemia and thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 3, 1999, Pages 311-319

  Mosesson, Michael W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dysfibrinogenemia; Embolism; Fibrinogen; Thrombophilia; Thrombosis

Indexed keywords

ANTITHROMBIN DEFICIENCY; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CALCIUM BINDING; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSFIBRINOGENEMIA; FIBRINOLYSIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN CROSS LINKING; PROTEIN POLYMERIZATION; PROTEIN SECRETION; THROMBOCYTE AGGREGATION; THROMBOPHILIA; THROMBOSIS;

EID: 0032765219     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994933     Document Type: Conference Paper

References (123)

1. Ebert R. Index of Variant Human Fibrinogens. Boca Raton, FL: CRC Press, 1994
2. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost 1995;73:151-161
3. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann NY Acad Sci 1983;408:28-43
4. Mosesson MW. Fibrinogen and fibrin polymerization: Appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coag Fibrinol 1997;8:257-267
5. Slayter HS. Electron microscopic studies of fibrinogen structure: Historical perspectives and recent experiments. Ann NY Acad Sci 1983;408:131-145
6. Mosesson MW, Hainfeld JF, Haschemeyer RH, Wall JS. Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy. J Mol Biol 1981;153:695-718
7. Williams RC. Morphology of fibrinogen monomers and of fibrin polymers. Ann NY Acad Sci 1983;408:180-193
8. 2-terminal part of human fibrinogen. Thromb Res 1976;8:639-658
9. Huang S, Cao Z, Davie EW. The role of amino-terminal disulfide bonds in the structure and assembly of human fibrinogen. Biochem Biophys Res Commun 1993;190:488-495
10. Zhang J-Z, Redman CM. Role of interchain disulfide bonds on the assembly and secretion of human fibrinogen. J Biol Chem 1994;269:652-658
11. Finlayson JS, Mosesson MW. Heterogeneity of human fibrinogen. Biochemistry 1963;2:42-46
12. Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ′). Biochemistry 1981;20:6146-6149
13. Townsend RR, Hilliker E, Li YT, et al. Carbohydrate structure of human fibrinogen. J Biol Chem 1982;257:9704-9710
14. Barnhart MI, Cress DC, Noonan SM, Walsh RT. Influence of fibrinolytic products on hepatic release and synthesis of fibrinogen. Thromb Haemost 1970;(Suppl 39):143-159
15. Fuller GM, Nickerson JM, Adams MA. Translation and cotranslational events in fibrinogen synthesis. Ann NY Acad Sci 1983;408:440-448
16. Olaisen B, Teissberg P, Gedde-Dahl T Jr. Fibrinogen γ chain locus is on chromosome 4 in man. Hum Genet 1982;61:24-26
17. Chung DW, Rixon MW, Que BG, Davie EW. Cloning of fibrinogen genes and their cDNA. Ann NY Acad Sci 1983;408:449-456
18. Crabtree GR, Kant JA, Fornace AJ Jr, Rauch CA, Fowlkes DM. Regulation and characterization of the mRNAs for the Aα, Bβ, and γ chains of fibrinogen. Ann NY Acad Sci 1983;408:457-466
19. Kant J, Fornace AJ Jr, Saxe D, et al. Organization and evolution of the human fibrinogen locus on chromosome four. Proc Natl Acad Sci (USA) 1985;82:2344-2348
20. Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972;22:681-700
21. Martinez J, Holburn RR, Shapiro SS, Erslev AJ. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. J Clin Invest 1974;53:600-611
22. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989;84:1320-1324
23. 3 (glycoprotein IIb-IIIa). Blood 1993;82:135-138
24. Handagama P, Amrani DL, Shuman MA. Endocytosis of fibrinogen into hamster megakaryocyte α granules is dependent on a dimeric γA configuration. Blood 1995;85:1790-1795
25. Mosesson MW, Homandberg GA, Amrani DL. Human platelet fibrinogen gamma chain structure. Blood 1984;63:990-995
26. Francis CW, Nachman RL, Murder VJ. Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost 1984;51:84-88
27. Kunicki TJ, Newman PJ, Amrani DL, Mosesson MW. Human platelet fibrinogen: Purification and hemostatic properties. Blood 1985;66:808-815
28. Scheraga HA, Laskowski M, Jr. The fibrinogen-fibrin conversion. Adv Prot Chem 1957;12:1-157
29. Blombäck B. Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv Kemi 1958;12:321-335
30. Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature (London) 1978;275:501-505
31. Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Proc Natl Acad Sci (USA) 1978;75:3085-3089
32. Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization: Structural requirements and species differences. Biochemistry 1980;19:1013-1019
33. Liu CY, Koehn JA, Morgan FJ. Characterization of fibrinogen New York I. A dysfunctional fibrinogen with a deletion of Bβ 9-72 corresponding exactly to exon 2 of the gene. J Biol Chem 1985;260:4390-4396
34. 2-terminus. J Biol Chem 1985;260:2994-3000
35. Shimizu A, Saito Y, Inada Y, Distinctive role of histidine-16 of the Bβ chain of fibrinogen in the end-to-end association of fibrin. Proc Natl Acad Sci (USA) 1986;83:591-593
36. Siebenlist KR, DiOrio JP, Budzynski AZ, Mosesson MW. The polymerization and thrombin-binding properties of des-(Bβ1-42)-fibrin. J Biol Chem 1990;265:18650-18655
37. Pandya BV, Gabriel JL, O'Brien JO, Budzynski AZ. Polymerization site in the β chain of fibrin: Mapping of the Bβ1-55 sequence. Biochemistry 1991;30:162-168
38. Kudryk B, Reuterby J, Blombäck B. Adsorption of plasmic fragment D to thrombin modified fibrinogen-sepharose. Thromb Res 1973;2:297-304
39. Kudryk B, Collen D, Woods KR, Blombäck B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem 1974;249:3322-3325
40. Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci (USA) 1980;77:1374-1378
41. Shimizu A, Nagel GM, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: Isolation of a CNBr fragment corresponding to g337-379. Proc Natl Acad Sci (USA) 1992;89:2888-2892
42. Yamazumi K, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: Localization of the label to γ-chain Tyr-363. Proc Natl Acad Sci (USA) 1992;89:2893-2896
43. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997;389:455-462
44. Ferry JD. The mechanism of polymerization of fibrinogen. Proc Natl Acad Sci (USA) 1952;38:566-569
45. Krakow W, Endres GF, Siegel BM, Scheraga HA. An electron microscopic investigation of the polymerization of bovine fibrin monomer. J Mol Biol 1972;71:95-103
46. Fowler WE, Hantgan RR, Hermans J, Erickson HP. Structure of the fibrin protofibril. Proc Natl Acad Sci (USA) 1981;78:4872-4876
47. Hantgan R, McDonagh J, Hermans J. Fibrin assembly. Ann NY Acad Sci 1983;408:344-365
48. Mosesson MW, Siebenlist KR, Amrani DL, DiOrio JP. Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci (USA) 1989;86:1113-117
49. Hewat EA, Tranqui L, Wade RH. Electron microscope structural study of modified fibrin and a related modified fibrinogen aggregate. J Mol Biol 1983;170:203-222
50. Mosesson, DiOrio JP, Siebenlist KR, Wall JS, Hainfeld JF. Evidence for a second type of branch point in fibrin polymer networks, the trimolecular junction. Blood 1993;82:1517-1521
51. Shainoff JR, Dardik BN. Fibrinopeptide B in fibrin assembly and metabolism: Physiologic significance in delayed release of the peptide. Ann NY Acad Sci 1983;408:254-267
52. Shainoff JR, Dardik BN. Fibrinopeptide B and aggregation of fibrinogen. Science 1979;204;200-202
53. Martinelli RA, Scheraga HA. Steady-state kinetic study of the bovine thrombin-fibrinogen interaction. Biochemistry 1980;19:2343-2350
54. Hurlet-Jensen A, Cummins HZ, Nossel HL, Liu CY, Fibrin polymerization and release of fibrinopeptide B by thrombin. Thromb Res 1982;27:419-427
55. Ruf W, Bender A, Lane DA, et al. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: Influence of inhibitors of fibrin polymerization. Biochim Biophys Acta 1988;965:169-175
56. Medved LV, Litvinovich SV, Ugarova TP, et al. Localization of a fibrin polymerization site complementary to Gly-His-Arg sequence. FEBS Lett 1993;320:239-242
57. Everse SJ, Spraggon G, Veerapandian L, Riley M, Doolittle RF. Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry 1998;37:8637-8642
58. Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS. The covalent structure of factor XIIIa-crosslinked fibrinogen fibrils. J Struct Biol 1995;115:88-101
59. Mosesson MW, Siebenlist KR, DiOrio JP, et al. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ275 Arg→Cys). J Clin Invest 1995;96:1053-1058
60. Siebenlist KR, Meh DA, Wall JS, Hainfeld JF, Mosesson MW. Orientation of the C-terminal regions of fibrin γ chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa. Thromb Haemost 1995;74:1113-1119
61. Niwa K, Takebe M, Sugo T, et al. A γ Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 1996;87:4686-4694
62. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the γ chain of hunan fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983;29:249-255
63. Kloczewiak M, Timmons S, Lucas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain. Biochemistry 1984;23:1767-1774
64. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: Evidence for an extended carboxyl-terminal sequence in a normal fibrinogen variant (γ′). Proc Natl Acad Sci (USA) 1980;77:5069-5073
65. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chains. Biochemistry 1996;35:10448-10453
66. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996;271:23121-23125
67. Mosesson MW, Sherry S. Preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966;5:2829-2835
68. Hasegawa N, Sasaki S. Location of the binding site "b" for lateral polymerization of fibrin. Thromb Res 1990;57:183-195
69. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. J Biol Chem 1993;268:13577-13585
70. Gorkun OV, Veklich YI, Medved LV, Henschen A, Weisel JW. Role of the aC domains of fibrin in clot formation. Biochemistry 1994;33:6986-6997
71. Fenton JW, II, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition. Biochemistry 1988;27:7106-7112
72. Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin's structure. Thromb Res 1993;69:1-58
73. Scheraga HA. Interaction of thrombin and fibrinogen and the polymerization of fibrin monomer. Ann NY Acad Sci 1983;408:330-343
74. Liu CY, Wallen P, Handley DA. Fibrinogen New York I: The structural, functional, and genetic defects and an hypothesis of the role of fibrin in the regulation of coagulation and fibrinolysis. In: Lane D, Henschen A, Jasani M, eds. Fibrinogen, Fibrin Formation, and Fibrinolysis, Vol 4. Berlin: Walter de Gruyter; 1986:79-90
75. Di Minno G, Martinez J, Cirillo F, et al. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). Arteriosclerosis Thromb 1991;11:785-796
76. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of Bβ68 Ala→Thr. J Clin Invest 1992;90:238-244
77. Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979;254:10421-10425
78. Vali Z, Scheraga HA. Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry 1988;27:1956-1963
79. Binnie CG, Lord ST. A synthetic analog of fibrinogen α27-50 is an inhibitor of thrombin. Thromb Haemost 1994;65:165-168
80. 44→Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci (USA) 1992;89:3478-3482
81. Engesser L, Koopman J, de Munk G. Fibrinogen Nijmegen: Congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 1988;60:113-120
82. Borrell M, Garí M, Coll C, et al. Abnormal polymerization and normal binding of plasminogen and t-PA in three new dysfibrinogenemias: Barcelona III and IV (γ275Arg→His) and Villajoyosa (γ275Arg→Cys): Blood Coag Fibrinol 1995;6:198-206
83. Steinmann C, Bögli C, Jungo M, et al. Fibrinogen Milano V. A congenital dysfibrinogenemia with a γ275 Arg→Cys substitution. Blood Coag Fibrinol 1994;5:463-471
84. Mosesson MW, Siebenlist KR, Olson JD. Thrombophilia associated with dysfibrinogenemia [fibrinogen Cedar Rapids (γR275C)] and a heterozygous factor V Leiden defect. Thromb Haemostas 1997;(Suppl) 382 (Abst)
85. Brook JG, Tabori S, Tatarsky I, Hashmonai M, Schramek A. Fibrinogen 'Haifa'-A new fibrinogen variant. Haemostasis 1983;13:277-281
86. Reber P, Furlan M, Henschen A, et al. Three abnormal fibrinogen variants with the same amino acid substitution (γ275Arg→His): Fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost 1986;56:401-406
87. Steinmann C, Jungo M, Beck EA, Lämmle B, Furlan M. Fibrinogen Claro-another dysfunctional fibrinogen variant with γ275 arginine→histidine substitution. Thromb Res 1996;81:145-150
88. Matsuda M, Baba M, Morimoto K, Nakamikawa C. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest 1983;72:1034-1041
89. Siebenlist KR, Mosesson MW, DiOrio JP, et al. The polymerization of fibrin prepared from fibrinogen Haifa (γ275 Arg→His). Thromb Haemost 1989;62:875-879
90. Niwa K, Kawata Y, Madoiwa S, et al. Fibrinogen Kamogawa: A new type of γArg-275 to Ser substitution characterized by delayed fibrin gel formation. Thromb Haemost 1995;73:1229 (Abst)
91. Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability: Congenital and acquired thrombophilias. Clin Appl Thromb/Hemostas 1998;4:25-50
92. Dahlbäck B. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-614
93. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation V associated with resistance to activated protein C. Nature 1994;369:64-76
94. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538
95. Greengard JS, Sun X, Xu X. et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1362-1363
96. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-1536
97. Dang CV, Ebert RF, Bell WR. Localization of a fibrinogen calcium binding site between γ-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 1985;260:9713-9717
98. Koopman J, Haverkate F, Briët E, Lord ST. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Cheat 1991;266:13456-13461
99. Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments. Thromb Res 1977;10:803-812
100. Galanakis DK, Spitzer SG, Scharrer I, Peerschke EL. Impaired platelet aggregation support by two dysfibrinogens: A γ319-320 deletion and a γ310Met→Thr substitution. Thromb Haemost 1993;69:2564 (Abst)
101. Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: A homozygous case of dysfibrinogenemia, lacking amino acid Aα461-610 (Lys 461 → AAA Stop TAA). Blood 1992;80:1972-1979
102. n-heteromultimers and the α-chain-linked albumin -γ complex, and disturbed protifibril assembly resulting in acquisition of plasmin resistance relevant to thrombophilia. Blood 1998;91:3282-3288
103. Furlan M. Steinmann C, Jungo M, et al. A frameshift mutation in exon V of the Aα-chain gene leading to truncated An chains in the homozygous dysfibrinogen Milano III. J Biol Chem 1994;269:33129-33134
104. Furlan M, Steinmann C, Lämmle B. Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα-chains. Blood Coag Fibrinol 1996;7:331-335
105. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure in fibrinolysis. J Biol Chem 1992;267:24259-24263
106. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinol 1995;6:567-573
107. Collet J-P, Soria J, Mirshahi M, et al. Dusart Syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood 1993;82:2462-2469
108. Soria J, Soria C, Caen JP. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusard syndrome: Possible relationship to thrombosis. Br J Haematol 1983;53:575-586
109. Lijnen HR, Soria J, Soria C, Collen D, Caen JP. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984;51:108-109
110. Koopman J, Haverkate F, Grimbergen J, et al. Molecular basis for fibrinogen Dusart (Aα544 Arg→Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993;91:1637-1643
111. Siebenlist KR, Mosesson MW, DiOrio JP, et al. The polymerization of fibrinogen Dusart (Aα554 Arg→Cys) after removal of carboxy-terminal regions of Aα chains. Blood Coag Fibrinol 1993;4:61-65
112. Mosesson MW, Siebenlist KR, Hainfeld JF, el al. The relationship between the fibrinogen D domain self-association/cross-linking site (γXL) and the fibrinogen Dusart abnormality (AαR544C-albumin). Clues to thrombophilia in the "Dusart Syndrome". J Clin Invest 1996;97:2342-2350
113. Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (Aα554 Arg→Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994;84:3709-3714
114. Arocha-Piñango CL, Torres A, Marchi R, et al. A new thrombotic dysfibrinogenemia present in several members of a Venezuelan Family. Thromb Haemst 1987;58:149(Abst)
115. Marchi R, Arocha-Piñango CL, Gil F. Electron microscopy studies of 7 patients with dysfibrinogenemia and some of their relatives. Rev Iberoamer Tromb Hemostasia 1990;3:185-190
116. Yamaguchi FI, Sugo T, Hashimoto Y, et al. Fibrinogen Kumamoto, with an Aa Arg19→Gly substitution associated clinically with thrombosis. Fibrinolysis 1996;10(Suppl 4):23(Abst)
117. Bentolila S, Samama MM, Conard J, Horellou MH, French P. Association of dysfibrinogenemia and thrombosis. Apropos of a family (fibrinogen Melun) and review of the literature. Ann Med Interne 1995;146:575-580
118. Okumura N, Furihata K, Terasawa F, et al. A γ364 Asp→His (GAT→CAT) substitution associated with defective fibrin polymerization. Thromb Haemost 1996;75:887-891
119. Brennan SO, Loreth RM, George PM. Oligosaccharide configuration of fibrinogen Kaiserslautern; Electrospray ionization analysis of intact γ chains. Thromb Haemost 1998;80:263-265
120. Ridgway HJ, Brennan SO, Loreth RM, George PM. Fibrinogen Kaiserslautern (γ380 Lys to Asn); A new glycosolated variant with delayed polymerization. Br J Haematol 1997;99:562-569
121. Soria J, Soria C, Hedner U, et al. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenemia (fibrinogen Malmöe). Br J Haematol 1985;61:727-738
122. Beck EA, Charache P, Jackson DP. A new inherited coagulation disorder caused by an abnormal fibrinogen ('Fibrinogen Baltimore'). Nature (London) 1965;208;143-145
123. Grailhe P, Boyer-Neumann C, Haverkate F, et al. The mutation in fibrinogen Bicêtre II (γAsn308→Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coag Fibrinol 1993;4:679-687